How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphomas after first-line chemotherapy when a stem cell transplant is suitable

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about lisocabtagene maraleucel

Marketing authorisation indication

2.1

Lisocabtagene maraleucel (liso‑cel; Breyanzi, Bristol-Myers Squibb) is indicated for 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL), high grade B‑cell lymphoma (HGBCL), primary mediastinal large B‑cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy'.

Price

2.3

The list price for a single infusion, including shipping, engineering and generation of CAR T‑cells is £297,000, (company submission, May 2024).

2.4

The company has a commercial arrangement, which would have applied if liso-cel had been recommended.